White label ELPA - ClinicalTrials.eu

Study on Continuing or Stopping Immunosuppressive Therapy with Rituximab in Patients with ANCA Vasculitis and End-stage Kidney Disease

Not recruiting

3 1 1 1
Investigated diseases:
- Anti-neutrophil cytoplasmic antibody positive vasculitis
- End stage renal disease
Investigated drugs:
Study of Stereotactic Body Radiotherapy with or without Darolutamide for Patients with Oligorecurrent Prostate Cancer

Not recruiting

2 1 1
Investigated diseases:
- Prostate cancer
Investigated drugs:
- Darolutamide
Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

Not recruiting

1 1 1 1
Investigated diseases:
- Triple negative breast cancer
Investigated drugs:
Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Not recruiting

3 1 1 1
Investigated diseases:
- Metastatic renal cell carcinoma
Investigated drugs:
+1
Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Not recruiting

3 1 1
Investigated diseases:
- Ovarian cancer stage III
- Ovarian cancer stage IV
Investigated drugs:
- Dostarlimab
- Niraparib Tosilate Monohydrate
+7
Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Not recruiting

3 1 1 1
Investigated diseases:
- Plasma cell myeloma
Investigated drugs:
+8
Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Not recruiting

3 1 1 1
Investigated diseases:
- Colorectal cancer
Investigated drugs:
+7
Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Not recruiting

3 1
Investigated diseases:
- Polycythaemia vera
Investigated drugs:
- Rusfertide
+5
Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

Not recruiting

3 1 1
Investigated diseases:
- Cardiovascular disorder
- Type IIa hyperlipidaemia
Investigated drugs:
- Lerodalcibep
Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Not recruiting

4 1 1 1
Investigated diseases:
- Metastatic malignant melanoma
- Malignant melanoma
Investigated drugs:
- Relatlimab
- Nivolumab
+7

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies